1 completed, 1 no longer available, 1 terminated, 1 withdrawn. 2 Phase 3, 1 Phase 1.
By phase and status
Follow EQRx International, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer
Lerociclib, Letrozole 2.5mg, Placebo - Endometrial Carcinoma | Phase 3 | Withdrawn | EQRx International, Inc. | | 2023-04-18 | 2023-11-03 |
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
Aumolertinib monotherapy, Osimertinib monotherapy, Pemetrexed - NSCLC | Phase 3 | Terminated | EQRx International, Inc. | 8 | 2022-12-14 | 2024-05-02 |
An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143
aumolertinib - Severe Hepatic Impairment | Phase 1 | Completed | EQRx International, Inc. | 12 | 2022-03-30 | 2023-04-19 |
An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)
sugemalimab - Extranodal NK/T-cell Lymphoma | | No longer available | EQRx International, Inc. | | | 2023-03-27 |
Conditions studied
Endometrial Neoplasms (1) · Lymphoma, Extranodal NK-T-Cell (1) · Recurrence (1)
Interventions
aumolertinib (2) · Albumin-Bound Paclitaxel (1) · Carboplatin (1) · Cisplatin (1) · Gemcitabine (1) · Letrozole (1) · Paclitaxel (1) · Pemetrexed (1) · Taxes (1) · osimertinib (1) · sugemalimab (1)
Countries
United States (3)